Synthetic Biologics, Inc.
9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850
May 7, 2021
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dillon Hagius
Re: Synthetic Biologics, Inc.
Registration Statement on Form S-3
File No. 333-255726
Ladies & Gentlemen:
Synthetic Biologics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-255726), be accelerated by the U.S. Securities and Exchange Commission to Tuesday, May 11, 2021 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|Very truly yours,|
|Synthetic Biologics, Inc.|
|By:||/s/ Steven A. Shallcross|
|Name:||Steven A. Shallcross|
|Title:||Chief Executive Officer and Chief Financial Officer|
|cc:||Leslie Marlow, Esq., Gracin & Marlow, LLP|
|Patrick Egan, Esq., Gracin & Marlow, LLP|